

Method Extension of CIPAC 578 in Flumioxazin SC

Test Facility: Name: Shandong Binnong Technology Co., Ltd.

Address: No.518, Yongxin Road, Binbei Town, Binzhou, Shandong, China

Tel: 86-543-5087891 Fax: 86-543-5087891

Sponsor: Name: Shandong Binnong Technology Co., Ltd.

Address: No.518, Yongxin Road, Binbei Town, Binzhou, Shandong, China

Tel: 86-543-3363985 Fax: 86-543-3163179

Chief Analyzer: Name: Ms. Sun Jing

Address: No.518, Yongxin Road, Binbei Town, Binzhou, Shandong, China

Tel: 86-543-5087153 Fax: 86-543-5087891

<u>Test Guideline:</u> CIPAC No. 3807, CIPAC 578



Content

Title Page	1
Content	2
STATEMENT	3
1. Summary	4
2. Introduction	5
3. Material	5
3.1 Specification of test item	5
3.2 Specification of reference item	5
3.3 Storage conditions	5
4. Experimental Procedure	6
4.1 Reagents	6
4.2 Equipment	6
4.3 Analytical condition	6
4.4 Specificity test	6
4.5 Linearity check	7
5. Result and Conclusion	7
5.1 Specificity test results	7
5.2 Linearity check results	8
6. Amendment and deviation	9
7. Reference	9
8. Appendix	9
APPENDIX A: COPY OF CHROMATOGRAM	10
FIGURE 1: CHROMATOGRAM OF ACETONITRILE, SOLVENT)	10
FIGURE 2: CHROMATOGRAM OF BLANK FORMULATION	11
FIGURE 3: CHROMATOGRAM OF REFERENCE ITEM	12
FIGURE 4: CHROMATOGRAM OF TEST ITEM	13
FIGURE 5: PEAK PURITY OF REFERENCE ITEM	14
FIGURE 6: PEAK PURITY OF TEST ITEM	15
FIGURE 7: LINEARITY CHECK FOR LIN-1, injection 1	16
FIGURE 8: LINEARITY CHECK FOR LIN-1, injection 2	17
FIGURE 9: LINEARITY CHECK FOR LIN-2, injection 1	18
FIGURE 10: LINEARITY CHECK FOR LIN-2, injection 2	19
FIGURE 11: LINEARITY CHECK FOR LIN-3, injection 1	
FIGURE 12: LINEARITY CHECK FOR LIN-3, injection 2	
APPENDIX B: CERTIFICATE OF ANALYSIS FOR TEST ITEM	22
APPENDIX C: CERTIFICATE OF ANALYSIS FOR REFERENCE ITEM	23



STATEMENT

Test substance: Flumioxazin SC

Study Title: Method Extension of CIPAC 578 in Flumioxazin SC

Study No.: BNS20220052

This study was designed and performed by QC Center of Shandong Binnong Technology Co., Ltd. To the best of our knowledge, there were no deviations from the study protocol affecting the quality or integrity of the study.

This report accurately reflects the raw data and accurately describes the methods and standard operation procedures used in this study.

Chief Analyzer: Sun Jing

Signature:

Date: 2022-06-08

Shandong Binnong Technology Co., Ltd.

Sun Jing



1. Summary

For Flumioxazin SC, there is no CIPAC method available. To determine whether the method (CIPAC 578) can be applied for the new formulation of Flumioxazin SC, a specificity test was performed according to the procedure of the extension of the scope of methods. The results are summarized in the following Table 1 and Table 2.

Table 1 The specificity test results

Solution tested	Conclusion
Acetonitrile (Solvent)	
Blank formulation	No interferences were detected at the
Test item solution	retention time of the active ingredient.
Reference item solution	

Table 2 Peak purity analysis results

Sample solution name	Purity threshold	Purity factor
Test item solution	990.000	999.944
Reference item solution	990.000	999.690

According to the specificity test and peak purity analysis results, the method (CIPAC 578) was considered specific applied for the Flumioxazin SC.

And the concentration of flumioxazin analyte is inside the acceptability range covered by the sample, so the method (CIPAC 578) can be applied for Flumioxazin SC.



2. Introduction

The objective of the study is to evaluate whether the method (CIPAC 578) is suitable for the determination of flumioxazin in SC formulation.

3. Material

3.1 Specification of test item

The related information and analytical identification provided by the sponsor was the responsibility of the sponsor. The details of the test items are given as follow:

Product name	Flumioxazin SC
Molecular formula of Al	C ₁₉ H ₁₅ FN ₂ O ₄
Molecular weight of Al	354.3 g/mol
Structure formula of Al	
Chemical name (IUPAC) of	N-(7-fluoro-3,4-dihydro-3-oxo-4-prop-2-ynyl-2H-1,4-
Al	benzoxazin-6-yl) cyclohex-1-ene-1,2-dicarboxamide
CAS No. of Al	103361-09-7
Physical state	Off-white liquid
Batch No.	202206007
Active ingredient, g/l (w/v)	482
Density, (g/cm ³)	1.174
Manufacture date	June 02, 2022
Retest date	June 02, 2024
Storage condition	Store in original container, in a well-ventilated, cool, dry,
	secure area.
Manufacturer	Shandong Binnong Technology Co., Ltd.
Address of manufacturer	No.518, Yongxin Road, Binbei Town, Binzhou, Shandong, China

Certificate of analysis for test item are presented in **Appendix B**.

3.2 Specification of reference item

Product Name	Flumioxazin
CAS Number	103361-09-7
Lot No.	G140220
Purity	99.47%
Certified date	May 26, 2017
Expiry Date	February 16, 2023
Storage Condition	20±4℃
Manufacturer	Dr. Ehrenstorfer

Certificate of analysis for reference item are presented in **Appendix C**.

3.3 Storage conditions

The test item was stored at 20±10 °C in Test Substance Control Office of BNS QC Center. The



reference item was stored at 20±4°C in refrigerator in BNS QC Center. They are treated according to relevant SOP for reception, storage and distribution.

4. Experimental Procedure

4.1 Reagents

Flumioxazin reference item, purity 99.47%, Lot No.: G140220, supplied by Dr. Ehrenstorfer.

Acetonitrile, HPLC grade, Lot No.: 10972907839, supplied by Merck KGaA, Germany.

Ultrapure water, resistivity: ≥10 MΩ·cm, prepared by ultrapure water machine.

4.2 Equipment

Agilent 1260 Infinity II LC system, with DAD detector, supplied by Agilent Technologies Pte., Ltd, USA;

Electronic balance, type: XSE205DU, supplied by Mettler-Toledo Instrument Co., Ltd, Switzerland.

Ultrapure water machine, type: UPR- $\rm II$ -20L, supplied by ULUPURE Ultrapure Technology Co., Ltd, China.

Ultrasonic cleaner, type: AS-3120, supplied by Tianjin Automatic Science Instrument Co., Ltd, China.

Volumetric flask, 100 ml, supplied by Tianjin Glass Instrument Manufacturing Co., Ltd, China. Nylon syringe filters, 0.22 μ m, supplied by Tianjin Heshi Science and Technology Development Ltd., China.

Disposable syringe, 5 mL, supplied by Henan Shu Guang Jian Shi Medical Apparatus and Instruments Co., Ltd., China.

4.3 Analytical condition

Detector: DAD Wavelength: 288 nm

Column: Phenomenex Gemini (250mm x 4.6mm x 5µm)

Column temperature: 40° C Injection volume: $10.0 \, \mu$ l

Mobile phase: Solvent A: Ultrapure Water

Solvent B: Acetonitrile

Stop time: 15 min
Post time 0 min

Time (min)	Flow (mL/min)	A (%)	B (%)
0	1.000	50	50

4.4 Specificity test

The specificity of the method was evaluated by injecting Acetonitrile (solvent used for solution preparation), blank formulation, test item solution and reference item solutions to check for any interfering peak at the retention time of the peak of interest.

Blank formulation solution preparation: 71.27mg of blank formulation was weighed into a 100 mL volumetric flask. About 80 mL Acetonitrile was added into flask and the flask was shaken to dissolve. The flask was placed in ultrasonic bath for 10 min, then cool to ambient temperature. The solution was made up to the mark using Acetonitrile and mixed well.



Test item solution preparation: 123.72mg of test item was weighed into a 100 mL volumetric flask. About 80 mL Acetonitrile was added into flask and the flask was shaken to dissolve. The flask was placed in ultrasonic bath for 10 min, then cool to ambient temperature. The solution was made up to the mark using Acetonitrile and mixed well.

Reference item solution preparation: 50.63mg of reference item was weighed into a 100 mL volumetric flask. About 80 mL Acetonitrile was added into flask and the flask was shaken to dissolve. The flask was placed in ultrasonic bath for 10 min, then cool to ambient temperature. The solution was made up to the mark using Acetonitrile and mixed well.

All the solutions were filtered through a 0.22 µm filter prior to analysis.

And inject at least 2 portions of Reference item solutions for system equilibration before performing the specificity test.

4.5 Linearity check

Check the linearity of the detector response by injecting 10 μ l of solutions with flumioxazin concentrations 0.5, 1 and 2 times that of the Reference item solution to determine whether the concentration of the flumioxazin is inside the acceptability range covered by the samples applied in the method (CIPAC 578).

Lin-1: 25.09mg of reference item was weighed into a 100 mL volumetric flask. About 80 mL Acetonitrile was added into flask and the flask was shaken to dissolve. The flask was placed in ultrasonic bath for 10 min, then cool to ambient temperature. The solution was made up to the mark using Acetonitrile and mixed well.

Lin-2: 50.03mg of reference item was weighed into a 100 mL volumetric flask. About 80 mL Acetonitrile was added into flask and the flask was shaken to dissolve. The flask was placed in ultrasonic bath for 10 min, then cool to ambient temperature. The solution was made up to the mark using Acetonitrile and mixed well.

Lin-3: 100.19mg of reference item was weighed into a 100 mL volumetric flask. About 80 mL Acetonitrile was added into flask and the flask was shaken to dissolve. The flask was placed in ultrasonic bath for 10 min, then cool to ambient temperature. The solution was made up to the mark using Acetonitrile and mixed well.

All the solutions were filtered through a 0.22 µm filter prior to analysis.

5. Result and Conclusion

5.1 Specificity test results

Table 1 Specificity of Flumioxazin SC

Solution tested	Conclusion
Acetonitrile (Solvent)	
Blank formulation	No interferences were detected at the
Test item solution	retention time of the active ingredient.
Reference item solution	

The specificity relevant chromatograms, are listed in Appendix A, figure 1-4.

Peak purity analysis was performed using a DAD detector to detect the presence of any other substance co-eluting with the analyte peak. The peak purity factor of the sample solutions was greater than the peak purity threshold, indicating that there was no interference. That shows a



good peak purity.

Table 2 Peak purity of Flumioxazin in the method

Sample solution name	Purity threshold	Purity factor
Test item solution	990.000	999.944
Reference item solution	990.000	999.690


The peak purity analysis related chromatograms, are listed in Appendix A, figure 5-6. From the above specificity test, the method (CIPAC 578) used for flumioxazin SC formulation is specific.

5.2 Linearity check results

From the CIPAC guideline "EXTENSION OF THE SCOPE OF METHODS", the acceptability range is from 200 % to 50 % of the concentration of an analyte in a sample studied.

The 3 concentrations (0.5, 1, 2 times) of the Flumioxazin Reference item solution, were injected with duplicate for each. The line was generated with slope, intercept and correlation coefficient data.

The linearity chromatograms, are listed in Appendix A, figure 7-12.



The correlation coefficient (r) is $\,>\,$ 0.99. over the range (200% ~ 50% of the nominal).

The test item solution injected for specificity test with peak area 4099.29883, is in the range of the linearity concentration.

Table 3 Peak area of Flumioxazin reference and test item solutions

Sample solution name	Lin-1	Lin-2	Lin-3
Average peak area for 2 injections	2039.49677	4039.52466	8003.60865
Peak area of Test item solution for specificity		4099.29883	
Peak area of Reference item solution for specificity		4069.88550	

From the table 3, the peak area of Test item solution for specificity is nearly with the peak area of Lin-2, which indicate the concentration of analyte in test item solution for specificity is nearly with the concentration of analyte in Lin-2(100% of nominal analyte concentration).

The other hand, the sample content is 41.2% (w/w)(482/1.174/1000*100%=41.1%, indicated



in sponsor COA), which contains the analyte flumioxazin concentration as follows: 123.72mg /100ml *1000* 41.1%= 508.5mg/l, and in the method (CIPAC 578), the nominal concentration of flumioxazin used as (50mg /100ml =500mg/l), so, the acceptability range is 508.5/500*100% =101.7%, which is in the acceptable range between 200% and 50%.

6. Amendment and deviation

The test is focus on the extension of the flumioxazin CIPAC method to flumioxazin SC formulation. The specificity test was conducted completely follow the CIPAC method without any change.

7. Reference

- (1) CIPAC No.3807 Guidelines on method validation to be performed in support of analytical methods for agrochemical formulations.
- (2) CIPAC Method (578/TC/M/3, 578/WP/M/3).
- (3) CIPAC guideline 'Extension of the scope of methods'.

8. Appendix

APPENDIX A: COPY OF CHROMATOGRAM

APPENDIX B: CERTIFICATE OF ANALYSIS FOR TEST ITEM

APPENDIX C: CERTIFICATE OF ANALYSIS FOR REFERENCE ITEM



APPENDIX A: COPY OF CHROMATOGRAM

Data File D:\HPLC\DA...LUMIOXAZIN\FLUMIOXAZIN 2022-06-07 17-17-09\004-P2-A4-Acetonitrile.D Sample Name: Acetonitrile

Acq. Operator : SYSTEM Seq. Line: 4 Acq. Instrument : LC 1260 DAD

Injection Date : 6/7/2022 6:05:51 PM

Inj : 1


Inj Volume : 10.000 µl Acq. Instrument : LC 1260 DAD

Acq. Method : D:\HPLC\Data\Flumioxazin\Flumioxazin 2022-06-07 17-17-09\flumioxazin.M

Last changed : 11/17/2021 8:30:46 AM by SYSTEM

Analysis Method : D:\HPLC\METHOD\FLUMIOXAZIN\flumioxazin-1.M

Last changed : 6/8/2022 4:13:11 PM by SYSTEM



_____ Area Percent Report

Sorted By Signal : 1.0000 : 1.0000 Multiplier Dilution Use Multiplier & Dilution Factor with ISTDs

No peaks found

*** End of Report ***

LC 1260 DAD 6/8/2022 4:17:18 PM SYSTEM

FIGURE 1: CHROMATOGRAM OF ACETONITRILE, SOLVENT)



Data File D:\HPLC\DATA\FLUMIOXAZIN\FLUMIOXAZIN 2022-06-07 17-17-09\005-P2-A5-Blank-SC.D Sample Name: Blank-SC


Acq. Operator : SYSTEM Seq. Line: 5 Location: P2-A-05 Inj: 1 Acq. Instrument : LC 1260 DAD Injection Date : 6/7/2022 6:21:47 PM

Inj Volume : 10.000 μl

Acq. Method : D:\HPLC\Data\Flumioxazin\Flumioxazin 2022-06-07 17-17-09\flumioxazin.M Last changed : 11/17/2021 8:30:46 AM by SYSTEM

Analysis Method : D:\HPLC\METHOD\FLUMIOXAZIN\flumioxazin-1.M

Last changed : 6/8/2022 4:13:11 PM by SYSTEM



Area Percent Report

: Sorted By Signal Multiplier 1.0000 : 1.0000 Dilution Use Multiplier & Dilution Factor with ISTDs

No peaks found

*** End of Report ***

LC 1260 DAD 6/8/2022 4:18:13 PM SYSTEM

Page 1 of 1

FIGURE 2: CHROMATOGRAM OF BLANK FORMULATION



Data File D:\HPLC\DA...MIOXAZIN\FLUMIOXAZIN 2022-06-07 17-17-09\006-P2-A6-Reference item.D Sample Name: Reference item


Acq. Operator : SYSTEM Seq. Line: 6 Acq. Instrument : LC 1260 DAD Location : P2-A-06 Inj : 1 Inj : . Inj Volume : 10.000 μl Injection Date : 6/7/2022 6:37:43 PM

: D:\HPLC\Data\Flumioxazin\Flumioxazin 2022-06-07 17-17-09\flumioxazin.M Acq. Method

: 11/17/2021 8:30:46 AM by SYSTEM Last changed

Analysis Method : D:\HPLC\METHOD\FLUMIOXAZIN\flumioxazin-1.M

Last changed : 6/8/2022 4:13:11 PM by SYSTEM



______ Area Percent Report

Sorted By . Signal Sorted By :
Multiplier :
Dilution : 1.0000 1.0000

Use Multiplier & Dilution Factor with ISTDs

Signal 1: DAD1 A, Sig=288,4 Ref=off

Peak RetTime Type Width Area Height Area # [min] [min] [mAU*s] [mAU] % 1 12.722 BB 0.2576 4069.88550 242.80446 100.0000

Totals : 4069.88550 242.80446

*** End of Report ***

LC 1260 DAD 6/8/2022 4:18:40 PM SYSTEM

FIGURE 3: CHROMATOGRAM OF REFERENCE ITEM



Data File D:\HPLC\DATA\FLUMIOXAZIN\FLUMIOXAZIN 2022-06-07 17-17-09\007-P2-A7-Sample-SC.D Sample Name: Sample-SC

Acq. Operator : SYSTEM Seq. Line: 7


Location : P2-A-07 Inj : 1 Acq. Instrument : LC 1260 DAD Injection Date : 6/7/2022 6:53:40 PM Inj Volume : 10.000 μl

: D:\HPLC\Data\Flumioxazin\Flumioxazin 2022-06-07 17-17-09\flumioxazin.M : 11/17/2021 8:30:46 AM by SYSTEM Acq. Method

Last changed

Analysis Method : D:\HPLC\METHOD\FLUMIOXAZIN\flumioxazin-1.M

Last changed : 6/8/2022 4:13:11 PM by SYSTEM



Area Percent Report ______

Sorted By Signal Sorted by
Multiplier : : 1.0000 1.0000

Use Multiplier & Dilution Factor with ISTDs

Signal 1: DAD1 A, Sig=288,4 Ref=off

Peak RetTime Type Width Area Height Area [min] [mAU*s] # [min] [mAU] 1 12.730 BB 0.2577 4099.29883 244.41884 100.0000

4099.29883 244.41884 Totals:

*** End of Report ***

LC 1260 DAD 6/8/2022 4:19:10 PM SYSTEM


FIGURE 4: CHROMATOGRAM OF TEST ITEM




Data File D:\HPLC\DA...MIOXAZIN\FLUMIOXAZIN 2022-06-07 17-17-09\006-P2-A6-Reference item.D Sample Name: Reference item

Purity results peak 1 at 12.722 min.

Signal DAD1 A, Sig=288,4 Ref=off (D:\HPLC\DA...XAZIN\FLUMIOXAZIN 2022-06-07 17-17-09\006-P2-





-> The purity factor is within the threshold limit. <-

Purity factor: 999.690 (120 of 120 spectra are within the threshold limit.)

Threshold : 990.000 (Set by user)

Reference : Nearest baseline spectrum (stored) (0.005)

Spectra : 120 (Selection automatic, All)

Warning : Spectral absorbances > 1000 mAU (see help for more information)

*** End of Report ***

LC 1260 DAD 6/8/2022 10:38:07 AM SYSTEM

FIGURE 5: PEAK PURITY OF REFERENCE ITEM





Data File D:\HPLC\DATA\FLUMIOXAZIN\FLUMIOXAZIN 2022-06-07 17-17-09\007-P2-A7-Sample-SC.D Sample Name: Sample-SC

Purity results peak 1 at 12.730 min.



Signal DAD1 A, Sig=288,4 Ref=off (D:\HPLC\DA...LUMIOXAZIN\FLUMIOXAZIN 2022-06-07 17-17-09\01





^{-&}gt; The purity factor is within the threshold limit. <-

Purity factor: 999.944 (121 of 121 spectra are within the threshold limit.)

Threshold : 990.000 (Set by user)
Reference : Nearest baseline spectrum (stored) (0.003)

: 121 (Selection automatic, All)

Warning : Spectral absorbances > 1000 mAU (see help for more information)

*** End of Report ***

LC 1260 DAD 6/8/2022 10:39:20 AM SYSTEM

Page 1 of 1

FIGURE 6: PEAK PURITY OF TEST ITEM



Data File D:\HPLC\DATA\FLUMIOXAZIN\FLUMIOXAZIN 2022-06-07 17-17-09\008-P2-A1-Lin-1.D Sample Name: Lin-1


Acq. Operator : SYSTEM Seq. Line: 8 Acq. Instrument : LC 1260 DAD Location : P2-A-01 Inj : 1 Inj Volume : 10.000 µl Injection Date : 6/7/2022 7:09:35 PM

: D:\HPLC\Data\Flumioxazin\Flumioxazin 2022-06-07 17-17-09\flumioxazin.M : 11/17/2021 8:30:46 AM by SYSTEM Acq. Method

Last changed

Analysis Method : D:\HPLC\METHOD\FLUMIOXAZIN\flumioxazin 1.M $\,$

Last changed : 6/8/2022 9:14:04 AM by SYSTEM



Area Percent Report ______

Sorted By Signal

Calib. Data Modified : 6/8/2022 8:32:43 AM

Multiplier : 1.0000 Dilution : 1.0000

Use Multiplier & Dilution Factor with ISTDs

Signal 1: DAD1 A, Sig=288,4 Ref=off

Peak RetTime Type Width Area Area [min] [mAU*s] %

1 12.721 BB 0.2579 2040.12903 100.0000 Flumioxazin

Totals : 2040.12903

*** End of Report ***

LC 1260 DAD 6/8/2022 9:23:08 AM SYSTEM

Page 1 of 1

FIGURE 7: LINEARITY CHECK FOR LIN-1, injection 1



Data File D:\HPLC\DATA\FLUMIOXAZIN\FLUMIOXAZIN 2022-06-07 17-17-09\009-P2-A1-Lin-1.D Sample Name: Lin-1

_____ Acq. Operator : SYSTEM Seq. Line: 9

Location: P2-A-01 Inj: 2 Acq. Instrument : LC 1260 DAD Injection Date : 6/7/2022 7:25:31 PM


Inj Volume : 10.000 μl

: D:\HPLC\Data\Flumioxazin\Flumioxazin 2022-06-07 17-17-09\flumioxazin.M : 11/17/2021 8:30:46 AM by SYSTEM Acq. Method

Last changed

Analysis Method : D:\HPLC\METHOD\FLUMIOXAZIN\flumioxazin 1.M $\,$

Last changed : 6/8/2022 9:14:04 AM by SYSTEM



Area Percent Report

Sorted By Signal

6/8/2022 8:32:43 AM Calib. Data Modified :

Multiplier : 1.0000 1.0000 Dilution Use Multiplier & Dilution Factor with ISTDs

Signal 1: DAD1 A, Sig=288,4 Ref=off

Peak RetTime Type Width Area Area Name

[min] [mAU*s]

1 12.732 BB 0.2575 2038.86450 100.0000 Flumioxazin

Totals : 2038.86450

*** End of Report ***

LC 1260 DAD 6/8/2022 9:23:28 AM SYSTEM

Page 1 of 1

FIGURE 8: LINEARITY CHECK FOR LIN-1, injection 2




Data File D:\HPLC\DATA\FLUMIOXAZIN\FLUMIOXAZIN 2022-06-07 17-17-09\010-P2-A2-Lin-2.D Sample Name: Lin-2

Acq. Operator : SYSTEM Seq. Line: 10 Acq. Instrument : LC 1260 DAD Location : P2-A-02 Inj : 1 Inj Volume : 10.000 µl Injection Date : 6/7/2022 7:41:26 PM

: D:\HPLC\Data\Flumioxazin\Flumioxazin 2022-06-07 17-17-09\flumioxazin.M : 11/17/2021 8:30:46 AM by SYSTEM Acq. Method

Last changed

Analysis Method : D:\HPLC\METHOD\FLUMIOXAZIN\flumioxazin 1.M $\,$



Area Percent Report ______

Sorted By Signal

Calib. Data Modified : 6/8/2022 8:32:43 AM

Multiplier : 1.0000 Dilution : 1.0000

Use Multiplier & Dilution Factor with ISTDs

Signal 1: DAD1 A, Sig=288,4 Ref=off

Peak RetTime Type Width Area Area [min] [mAU*s] %

1 12.721 BB 0.2577 4038.73486 100.0000 Flumioxazin

Totals : 4038.73486

*** End of Report ***

LC 1260 DAD 6/8/2022 9:23:45 AM SYSTEM

Page 1 of 1

FIGURE 9: LINEARITY CHECK FOR LIN-2, injection 1



Data File D:\HPLC\DATA\FLUMIOXAZIN\FLUMIOXAZIN 2022-06-07 17-17-09\011-P2-A2-Lin-2.D Sample Name: Lin-2


Acq. Operator : SYSTEM Seq. Line: 11 Acq. Instrument : LC 1260 DAD Location : P2-A-02 Inj : 2 Injection Date : 6/7/2022 7:57:22 PM rnj . _ Inj Volume : 10.000 μl

: D:\HPLC\Data\Flumioxazin\Flumioxazin 2022-06-07 17-17-09\flumioxazin.M : 11/17/2021 8:30:46 AM by SYSTEM Acq. Method

Last changed

Analysis Method : D:\HPLC\METHOD\FLUMIOXAZIN\flumioxazin 1.M

Last changed : 6/8/2022 9:14:04 AM by SYSTEM



______ Area Percent Report

Sorted By Signal

Calib. Data Modified : 6/8/2022 8:32:43 AM

Multiplier : Dilution : 1.0000 1.0000

Use Multiplier & Dilution Factor with ISTDs

Signal 1: DAD1 A, Sig=288,4 Ref=off

Peak RetTime Type Width Area Area [min] [mAU*s] % # [min] 1 12.736 BB 0.2583 4040.31445 100.0000 Flumioxazin

Totals : 4040.31445

*** End of Report ***

LC 1260 DAD 6/8/2022 9:24:02 AM SYSTEM

FIGURE 10: LINEARITY CHECK FOR LIN-2, injection 2



Data File D:\HPLC\DATA\FLUMIOXAZIN\FLUMIOXAZIN 2022-06-07 17-17-09\012-P2-A3-Lin-3.D Sample Name: Lin-3


Acq. Operator : SYSTEM Seq. Line: 12 Acq. Instrument : LC 1260 DAD Location : P2-A-03 Inj : 1 Inj Volume : 10.000 µl Injection Date : 6/7/2022 8:13:19 PM

: D:\HPLC\Data\Flumioxazin\Flumioxazin 2022-06-07 17-17-09\flumioxazin.M : 11/17/2021 8:30:46 AM by SYSTEM Acq. Method

Last changed

Analysis Method : D:\HPLC\METHOD\FLUMIOXAZIN\flumioxazin 1.M

Last changed : 6/8/2022 9:14:04 AM by SYSTEM



______ Area Percent Report

Sorted By Signal

Calib. Data Modified : 6/8/2022 8:32:43 AM

Multiplier : Dilution : 1.0000 1.0000

Use Multiplier & Dilution Factor with ISTDs

Signal 1: DAD1 A, Sig=288,4 Ref=off

Area Peak RetTime Type Width Area [min] [mAU*s] % 1 12.726 BB 0.2573 8005.55225 100.0000 Flumioxazin

Totals : 8005.55225

*** End of Report ***

LC 1260 DAD 6/8/2022 9:24:21 AM SYSTEM

FIGURE 11: LINEARITY CHECK FOR LIN-3, injection 1





Data File D:\HPLC\DATA\FLUMIOXAZIN\FLUMIOXAZIN 2022-06-07 17-17-09\013-P2-A3-Lin-3.D Sample Name: Lin-3


______ Acq. Operator : SYSTEM Sea. Line : 13 Location : P2-A-03 Acq. Instrument : LC 1260 DAD Inj : 2 Injection Date : 6/7/2022 8:29:14 PM

Inj Volume : 10.000 μl

Acq. Method : D:\HPLC\Data\Flumioxazin\Flumioxazin 2022-06-07 17-17-09\flumioxazin.M Last changed : 11/17/2021 8:30:46 AM by SYSTEM

Analysis Method : D:\HPLC\METHOD\FLUMIOXAZIN\flumioxazin 1.M

Last changed : 6/8/2022 9:14:04 AM by SYSTEM



Area Percent Report

6/8/2022 8:32:43 AM Calib. Data Modified :

Multiplier : 1.0000 Dilution 1.0000 Use Multiplier & Dilution Factor with ISTDs

Signal 1: DAD1 A, Sig=288,4 Ref=off

Peak RetTime Type Width Area Area Name [min] [mAU*s] % ----1 12.740 BB 0.2580 8001.66504 100.0000 Flumioxazin

Totals : 8001.66504

*** End of Report ***

LC 1260 DAD 6/8/2022 9:24:48 AM SYSTEM

FIGURE 12: LINEARITY CHECK FOR LIN-3, injection 2



APPENDIX B: CERTIFICATE OF ANALYSIS FOR TEST ITEM



CERTIFICATE OF ANALYSIS

Product Name		Flumioxazin SC	
Manufacture Date	June 02, 2022	Test Date	June 02, 2022
Batch No.	202206007	Expiry Date	June 02, 2024
75 7	Test Result &	& Conclusion	
Analysis Ite	ms	Specification	Test results
Appearanc	e	Off-white liquid	Off-white liquid
Active ingredient,	g/1 (w/v)	≥ 480	482
Density (g/ca	m^3)	1.17	74
Storage cond		ore in original contains	

All the items are qualified for use and transport

Report Date: June 02, 2022

Chief Analyzer: Sun Jing Examiner: Song Shuyan Inspector: Geng Diangang

SHANDONG BINNONG TECHNOLOGY CO., LTD. Stamp:

Date: June 02, 20

FACTORY:

地址: 中国山东省滨州市滨北办事处永莘路518号

P.C.: 256600

Website: www.binnong.com

SALES COMPANY:

地址: 中国山东省滨州市黄河11路1111号

ADD: NO.518, YONGXIN ROAD, BINDEI TOWN, BINZHOU, SHANDONG, CHINA ADD: NO. 1111, HUANGHE 11 ROAD, BINZHOU CITY, SHANDONG PROVINCE, CHINA

TEL: +86-543-3368839/3367311 FAX: +86-543-3356775/3363612



Study Number: BNS20220052

APPENDIX C: CERTIFICATE OF ANALYSIS FOR REFERENCE ITEM

_						A .
rec				D- F	bronoto-fo-	Λ
				Dr. E	hrenstorfer	Materials for
Certific	ate of Analys	cic			Residue	Analysis
	Reference Material	313				
Product Identi	fication					
Article Name:	DRE-C13725000 Flumioxazin				Lot Number: Expiry Date:	G140220 16.02.2023
Formula: Mol. Weight:	C19H15FN2O4				Storage Temperature:	20°C ± 4°C
CAS No.:	103361-09-7					
Storage and hand	ling: The RM should be stored	in the original sealed bottle	at the temperatur given above.	After use the bottle should be	tightly closed and protected from mo	pisture and light. The expiry
date is valid for o	riginal sealed bottles under rec	commended storage conditi	ions only.			- 38 0
	Purity:	99.47% (g/g)				
	Evenedad Lincostalety Lie	1.05% (a/a)				
uncertainty is U(o operation involve of stability test lo Minimum sample four for a quarter	xp) = u(RM) x k, where k is the d in the analysis of the product ng-term; u(sts) uncertainty of s : 1 mg is recommended as the of sample.	coverage factor at the 95% t: u(RM) = vu(char) ² + u(bb) stability test short-term. u(i minimal sample amount. If	is confidence level (k=2). Uncertal poly 2 + u(lts)² + u(sts)² ; u(char) is the poly and u(sts) are not included in filess material is used, it is recom	ity u(RM) is based on the com uncertainty of purity determi the calculation as the stability	in Analytical Measurement, Second E bihation of the uncertainties associet ratifion; ubb) uncertainty of homogen statement is based on real evidence ed uncertainty by a factor of two for	ed with each individual neity test; u(its) uncertainty opposed to simulation.
uncertainty is U(e operation involve of stability test io Minimum sample four for a quarter Intended use: Use	f this standard is calculated in xx) = u(RM) × k, where k is the d in the analysis of the product rg-term; u(sts) uncertainty of s 1. mg is recommended as the	accordance with the ISO Gu coverage factor at the 95% LigRMI = Vu(char)* = v(bb) tability test short-term. u(t minimal sample amount. If	is confidence level (k=2). Uncertal poly 2 + u(lts)² + u(sts)² ; u(char) is the poly and u(sts) are not included in filess material is used, it is recom	ity u(RM) is based on the com uncertainty of purity determi the calculation as the stability	bination of the uncertainties associat nation; u(bb) uncertainty of homogen statement is based on real evidence	ed with each individual neity test; u(its) uncertainty opposed to simulation.
uncertainty is U(e operation involve of stability test lo Minimum sample four for a quarter Intended use: Use Analytical Data	f this standard is calculated in in the standard is calculated in in the analysis of the product on the product of the product	accordance with the ISO Gu coverage factor at the 95% cu (#RM) = Vu(Arr) + u(bb) tability test short-term. (If minimal sample amount, it setography or any other an	is confidence level (k=2). Uncertal poly 2 + u(lts)² + u(sts)² ; u(char) is the poly and u(sts) are not included in filess material is used, it is recom	ity u(RM) is based on the com uncertainty of purity determi the calculation as the stability	bination of the uncertainties associat nation; u(bb) uncertainty of homogen statement is based on real evidence	ed with each individual neity test; u(its) uncertainty opposed to simulation.
uncertainty is U(c operation involve of stability test lo Minimum sample four for a quarter intended use: Use Analytical Data Traceability of ch intrument:	f this standard is calculated in in july u ([M]) x k, where k is the in the analysis of the product on the product of the pr	accordance with the ISO Gu coverage factor at the 95% cu (#RM) = Vu(Arr) + u(bb) tability test short-term. (If minimal sample amount, it setography or any other an	is confidence level (k=2). Uncertail * * utilital* util	ity u(RM) is based on the com uncertainty of purity determi the calculation as the stability	bination of the uncertainties associat nation; u(bb) uncertainty of homogen statement is based on real evidence	ed with each individual neity test; u(its) uncertainty opposed to simulation.
uncertainty is U(o operation involve of stability test io Minimum sample four for a quarter intended use: Us Analytical Data Traceability of ch intrument: Detection: Column:	f this standard is calculated in in july un(RM) x k, where k is the in the analysis of the product on the product of the pro	accordance with the ISO Gu coverage factor at the 95% E. u(RiN) = vu(char)* + u(b). Tability test short-term. u(i minimal sample amount. It natography or any other an onal System of Units (SI).	is confidence level (le-2). Uncertail y - 'u (lts) ² - u(lts) ² ; u(char) is the ts) and u(sts) are not included in if less material is used, it is recom salytical technique.	ity u(RM) is based on the com uncertainty of purity determi the calculation as the stability	bination of the uncertainties associat nation; u(bb) uncertainty of homogen statement is based on real evidence	ed with each individual neity test; u(its) uncertainty opposed to simulation.
uncertainty is U(e operation involve of stability test lo Minimum sample four for a quarter intended use: Use Analytical Data	if this standard is calculated in in sp) = u(RM) x k, where k is the in the analysis of the product petern (usp) uncertainty of a sample. 1 mg is recommended as the of sample, this RM as calibrant for chron the standard property of the internation of the inte	accordance with the ISO Gu coverage factor at the 95% E. u(RiN) = vu(char)* + u(b). Tability test short-term. u(i minimal sample amount. It natography or any other an onal System of Units (SI).	is confidence level (k=2). Uncertail * * utilital* util	ity u(RM) is based on the com uncertainty of purity determi the calculation as the stability	bination of the uncertainties associat nation; u(bb) uncertainty of homogen statement is based on real evidence	ed with each individual neity test; u(its) uncertainty opposed to simulation.
uncertainty is U(o operation involve of stability test io Minimum sample four for a quarter intended use: Use Analytical Data Traceability of ch intrument: Detection: Column: injVol.: Flow:	f this standard is calculated in in july u ([M]) x k, where k is the ground in the analysis of the product on the product of	accordance with the ISO Gu coverage factor at the 95% E. u(RiN) = vu(char)* + u(b). Tability test short-term. u(i minimal sample amount. It natography or any other an onal System of Units (SI).	is confidence level (k=2). Uncertail * * utilital* util	ity u(RM) is based on the com uncertainty of purity determi the calculation as the stability	bination of the uncertainties associat nation; u(bb) uncertainty of homogen statement is based on real evidence	ed with each individual neity test; u(its) uncertainty opposed to simulation.
uncertainty is U(u) operation involved of stability test in Minimum sample flour for a quarter intended use: Use the transaction of the transactio	f this standard is calculated in spl = u(RM) x k, where k is the spl = u(RM) x k, where k is the inthe analysis of the product right and the spl = understood as the of sample. Tomatography: To the Internati HPLC/DAD DAD Reprosil 100 CL8 5 µm 250 x 10 µl 1.0 m/min 1.62 min	accordance with the ISO Gu coverage factor at the 95% u(RM) = Vu(Am)* + u(bb) tability test short-term. u(i minimal sample amount. It natography or any other an ional System of Units (SI). 3 mm	ic confidence level (k=2). Uncertal i * u/ltp1* u/ltp2* u/ltp1* u/lt	ity u(RM) is based on the com uncertainty of purity determi the calculation as the stability	bination of the uncertainties associat nation; u(bb) uncertainty of homogen statement is based on real evidence	ed with each individual neity test; u(its) uncertainty opposed to simulation.
uncertainty is U(u) operation involved of stability test in Minimum sample flour for a quarter intended use: Use the control of the control o	f this standard is calculated in top = u(RM) x k, where k is the unit point of the product net-term; u(sts) uncertainty of s 1. mg is recommended as the of sample. The product of sample will be the sample of	accordance with the ISO Gu coverage factor at the 95% u(RM) = Vu(Am)* + u(bb) tability test short-term. u(i minimal sample amount. It natography or any other an ional System of Units (SI). 3 mm	ic confidence level (k=2). Uncertal i * u/ltp1* u/ltp2* u/ltp1* u/lt	ity u(RM) is based on the com uncertainty of purity determi the calculation as the stability	bination of the uncertainties associat nation; u(bb) uncertainty of homogen statement is based on real evidence	ed with each individual neity test; u(its) uncertainty opposed to simulation.
ancertainty is U(a) operation involved of stability test to withintum sample four for a quarter netended use: Use Analytical Data fraceability of chintrument: betection: bolumn: ani, i-Vol.: 170wc Ret.Time: Comment fraceability: The Zalibrated class A zarrificate Revisit of last of the programment of the programmen	f this standard is calculated in in the plant of the product of th	accordance with the ISO Gu coverage factor at the 95% u(RM) = Vu(Am)* + u(bb) tability test short-term. u(i minimal sample amount. It natography or any other an ional System of Units (SI). 3 mm	ic confidence level (k=2). Uncertal i * u/ltp1* u/ltp2* u/ltp1* u/lt	ity u(RM) is based on the com uncertainty of purity determi the calculation as the stability	bination of the uncertainties associat nation; u(bb) uncertainty of homogen statement is based on real evidence	ed with each individual neity test; u(its) uncertainty opposed to simulation.
uncertainty is U(u) operation involved of stability test in Minimum sample flour for a quarter intended use: Use the control of the control o	f this standard is calculated in in the plant of the product of th	accordance with the ISO Gu coverage factor at the 95% u(RM) = Vu(Am)* + u(bb) tability test short-term. u(i minimal sample amount. It natography or any other an ional System of Units (SI). 3 mm	ic confidence level (k=2). Uncertal i * u/ltp1* u/ltp2* u/ltp1* u/lt	ity u(RM) is based on the com uncertainty of purity determi the calculation as the stability	bination of the uncertainties associat nation; u(bb) uncertainty of homogen statement is based on real evidence	ed with each individual neity test; u(its) uncertainty opposed to simulation.
uncertainty is U(u) operation involved of stability test to Minimum sample four for a quarter intended use: Us Analytical Data Traceability of chiral minimum continuation of the Column: Industrial traceability of chiral minimum column: Industrial minimum column: I	f this standard is calculated in in jul = u(fM) x k, where k is the in the analysis of the product in the area with the product of the produc	accordance with the ISO Gu coverage factor at the 95% LEMM1 = Vol. (APM1 = Vol. (AP	ic confidence level (k=2). Uncertal i * u/ltp1* u/ltp2* u/ltp1* u/lt	ity u(RM) is based on the com uncertainty of purity determi the calculation as the stability	bination of the uncertainties associat nation; u(bb) uncertainty of homogen statement is based on real evidence	ed with each individual neity test; u(its) uncertainty opposed to simulation.
uncertainty is U(operation involved of stability test to Minimum sample of stability test to Minimum sample four for a quarter intended use: Use Analytical Data fraceability of chintrument: Detection: Column: and the colum	f this standard is calculated in in the plant of the product of th	accordance with the ISO Gu coverage factor at the 95% LEMM1 = Vol. (APM1 = Vol. (AP	ic confidence level (k=2). Uncertal i * u/ltp1* u/ltp2* u/ltp1* u/lt	ity u(RM) is based on the com uncertainty of purity determi the calculation as the stability	bination of the uncertainties associat nation; u(bb) uncertainty of homogen statement is based on real evidence	ed with each individual neity test; u(its) uncertainty opposed to simulation.
ancertainty is U(u) peration involved of stability test to involved in stability test to involved in stability test to involved in stability of analytical Data fraceability of christopher involved in involved in involved invol	f this standard is calculated in in jul = u(fM) x k, where k is the in the analysis of the product in the area with the product of the produc	accordance with the ISO Gu coverage factor at the 95% LEMM1 = Vol. (APM1 = Vol. (AP	ic confidence level (k=2). Uncertal i * u/ltp1* u/ltp2* u/ltp1* u/lt	ity u(RM) is based on the com uncertainty of purity determi the calculation as the stability	bination of the uncertainties associat nation; u(bb) uncertainty of homogen statement is based on real evidence	ed with each individual neity test; u(its) uncertainty opposed to simulation.
ancertainty is U(u) peration involved of stability test to involved in stability test to involved in stability test to involved in stability of analytical Data fraceability of christopher involved in involved in involved invol	f this standard is calculated in in jul = u(fM) x k, where k is the in the analysis of the product in the area with the product of the produc	accordance with the ISO Gu coverage factor at the 95% LEMM1 = Vol. (APM1 = Vol. (AP	ic confidence level (k=2). Uncertal i * u/ltp1* u/ltp2* u/ltp1* u/lt	ity u(RM) is based on the com uncertainty of purity determi the calculation as the stability	bibliation of the uncertainties associal training and the state of the uncertainty of homogen statement is based on real evidence led uncertainty by a factor of two for it was not to the uncertainty by a factor of two for it was not to the uncertainty by a factor of two for it was not to the uncertainty by a factor of two for it was not the uncertainty by a factor of two for it was not the uncertainty by a factor of two for it was not the uncertainty by a factor of two for it was not the uncertainty by a factor of two for it was not the uncertainty by a factor of two for it was not the uncertainty by a factor of two for its way to the uncertainty by a factor of two for its way to the uncertainty by a factor of two for its way to the uncertainty by a factor of two for its way to the uncertainty by a factor of two for its way to the uncertainty by a factor of two for its way to the uncertainty by a factor of two for its way to the uncertainty by a factor of two for its way to the uncertainty by a factor of two for its way to the uncertainty by a factor of two for its way to the uncertainty by a factor of two for its way to the uncertainty by a factor of two for its way to the uncertainty by a factor of two for its way to the uncertainty by a factor of two factor of two factors was the uncertainty by the u	ed with each individual belip test, u(its) uncertainty opposed to simulation. half sample and a factor of
ancertainty is U(u) peration involved of stability test to involved in stability test to involved in stability test to involved in stability of analytical Data fraceability of christopher involved in involved in involved invol	f this standard is calculated in in jul = u(fM) x k, where k is the in the analysis of the product in the area with the product of the produc	accordance with the ISO Gu coverage factor at the 95% LEMM1 = Vol. (APM1 = Vol. (AP	ic confidence level (k=2). Uncertal it is utilized to the task and util	ity u(RM) is based on the com uncertainty of purity determi the calculation as the stability	bination of the uncertainties associat nation; u(bb) uncertainty of homogen statement is based on real evidence	ed with each individual belief test, villo, uncertainty opposed to simulation. half sample and a factor of

The LGC Labor GmbH, accreditated by DAKAS as indicated by the accreditation number 0-8M-19883-01. & 0-P4-19883-01, has shown competence based on EOS Guide 34-2009 with relevant parts of DINE NISO/BIC 27082-2005 for production of cartified reference materials in form of organic pure substances and in form of single and multi-component solutions of organic pure substances.

LGC Labor GmbH - Bgm.-Schlosser-Straße 6A - 86199 Augsburg - Germany Phone +49 821 906080 - Fax +49 821 9060888 - augsburg.ingulry@lgcgroup.com The warranty for this product is limited to the purchasing price of this product.

To be continue

\

Study Number: BNS20220052



Data File L:\GERÄTE BACKUP\DAD4\2017\2017KW07\130217-2 2017-02-13 15-53-28\13725000.D

Operator : SYSTEM Seq. Line : 28

Acq. Operator : SYSTEM Seq. Line : 28
Acq. Instrument : LCMS Location : 54
Injection Date : 13.02.2017 21:49:12 Inj : 1

Inj Volume : 10.000 µl

Acq. Method : C:\Chem32\1\Data\2017KW07\130217-2 2017-02-13 15-53-28\41K.M

Last changed : 13.02.2017 15:53:29 by SYSTEM

Last changed : 13.02.2017 15:53:29 by SYSTEM
Analysis Method : L:\GERÄTE BACKUP\DAD3\METHODS\41K.M
Last changed : 10.11.2015 09:04:07 by DAD3_Admin

Method Info : Acetonitrile : Water 4:1

Sample Info : Flumioxazin

Additional Info : Peak(s) manually integrated

*DAD1, Sig=212.00, 2.00 Ref=off, EXT of 13725000.D

mAU

17515012550250

Area Percent Report

Sorted By : Retention Time
Multiplier : 1.0000
Dilution : 1.0000
Use Multiplier & Dilution Factor with ISTDs

Signal 1: DAD1, Sig=212.00, 2.00 Ref=off, EXT Signal has been modified after loading from rawdata file!

Totals: 717.47504 196.52742

*** End of Report ***

LCMS 14.02.2017 15:32:20 SYSTEM